

Aggressively advance
cetorelix in BPH

- ▶ Flagship product candidate with significant near-term potential
- ▶ Retain all rights in BPH and fully support development through to NDA filing in 2009

Focus on further development of ozarelix and perifosine with current partners to ensure continued development success

A NEW FOCUSED DRUG DEVELOPMENT STRATEGY

Establish risk-adverse profile targeting earlier-stage compounds with high potential for aggressive development

Build solid endocrinology and oncology franchises

EMERGE AS A FULLY-INTEGRATED, GLOBAL SPECIALIST-DRIVEN BIOPHARMACEUTICAL COMPANY WITH A STRATEGIC FOCUS ON ENDOCRINE THERAPY AND ONCOLOGY